DK2045241T3 - Fluorsubstituerede cycloalkanoindoler og anvendelse deraf som prostaglandin D2-receptorantagonister - Google Patents

Fluorsubstituerede cycloalkanoindoler og anvendelse deraf som prostaglandin D2-receptorantagonister

Info

Publication number: DK2045241T3
Authority: DK; Denmark
Prior art keywords: prostaglandin; fluoro; receptor antagonists; cycloalkanoindoles; substituted
Prior art date: 2002-01-24

Application number

DK08105552.7T

Other languages

English (en)

Inventor

Carl Berthelette

Nicolas Lachance

Lianhai Li

Claudio Sturino

Zhaoyin Wang

Original Assignee

Merck Canada Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2002-01-24

Filing date

2003-01-22

Publication date

2012-10-15

2003-01-22 Application filed by Merck Canada Inc filed Critical Merck Canada Inc

2012-10-15 Application granted granted Critical

2012-10-15 Publication of DK2045241T3 publication Critical patent/DK2045241T3/da

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/56—Ring systems containing three or more rings
- C07D209/80—[b, c]- or [b, d]-condensed
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/06—Antiabortive agents; Labour repressants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/56—Ring systems containing three or more rings
- C07D209/80—[b, c]- or [b, d]-condensed
- C07D209/82—Carbazoles; Hydrogenated carbazoles
- C07D209/88—Carbazoles; Hydrogenated carbazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the ring system

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Physical Education & Sports Medicine (AREA)
Immunology (AREA)
Rheumatology (AREA)
Pulmonology (AREA)
Diabetes (AREA)
Cardiology (AREA)
Orthopedic Medicine & Surgery (AREA)
Pain & Pain Management (AREA)
Heart & Thoracic Surgery (AREA)
Endocrinology (AREA)
Biomedical Technology (AREA)
Neurology (AREA)
Neurosurgery (AREA)
Ophthalmology & Optometry (AREA)
Hematology (AREA)
Reproductive Health (AREA)
Urology & Nephrology (AREA)
Transplantation (AREA)
Oncology (AREA)
Anesthesiology (AREA)
Obesity (AREA)
Vascular Medicine (AREA)
Hospice & Palliative Care (AREA)
Otolaryngology (AREA)
Emergency Medicine (AREA)

DK08105552.7T 2002-01-24 2003-01-22 Fluorsubstituerede cycloalkanoindoler og anvendelse deraf som prostaglandin D2-receptorantagonister DK2045241T3 (da)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US35138402P	2002-01-24	2002-01-24
EP03700740A EP1470107B1 (en)	2002-01-24	2003-01-22	Fluoro substituted cycloalkanoindoles and their use as prostaglandin d2 receptor antagonists

Publications (1)

Publication Number	Publication Date
DK2045241T3 true DK2045241T3 (da)	2012-10-15

Family

ID=27613492

Family Applications (2)

Application Number	Title	Priority Date	Filing Date
DK08105552.7T DK2045241T3 (da)	2002-01-24	2003-01-22	Fluorsubstituerede cycloalkanoindoler og anvendelse deraf som prostaglandin D2-receptorantagonister
DK03700740T DK1470107T3 (da)	2002-01-24	2003-01-22	Fluor-substituerede cykloalkanoindoler og anvendelser heraf som prostaglandin D2-receptorantagonister

Family Applications After (1)

Application Number	Title	Priority Date	Filing Date
DK03700740T DK1470107T3 (da)	2002-01-24	2003-01-22	Fluor-substituerede cykloalkanoindoler og anvendelser heraf som prostaglandin D2-receptorantagonister

Country Status (39)

Country	Link
US (6)	US20030158246A1 (da)
EP (3)	EP1470107B1 (da)
JP (2)	JP4008885B2 (da)
KR (2)	KR100859230B1 (da)
CN (3)	CN101851191A (da)
AR (1)	AR038136A1 (da)
AT (1)	ATE414690T1 (da)
AU (1)	AU2003202343B2 (da)
BR (1)	BR0307050A (da)
CA (1)	CA2471952C (da)
CY (3)	CY1108841T1 (da)
DE (2)	DE60324767D1 (da)
DK (2)	DK2045241T3 (da)
DO (1)	DOP2003000566A (da)
EA (1)	EA006134B1 (da)
EC (1)	ECSP045203A (da)
EG (1)	EG24978A (da)
ES (2)	ES2316717T3 (da)
FR (1)	FR09C0010I2 (da)
GE (1)	GEP20074078B (da)
HR (1)	HRP20040665B1 (da)
IL (3)	IL162825A0 (da)
IS (2)	IS2633B (da)
JO (1)	JO2481B1 (da)
LU (1)	LU91534I2 (da)
MX (1)	MXPA04007167A (da)
MY (1)	MY137040A (da)
NL (1)	NL300377I2 (da)
NO (3)	NO327322B1 (da)
NZ (1)	NZ533786A (da)
PE (1)	PE20030982A1 (da)
PL (1)	PL208527B1 (da)
PT (2)	PT2045241E (da)
RS (2)	RS20100338A (da)
SI (2)	SI1470107T1 (da)
TW (1)	TWI259080B (da)
UA (1)	UA75520C2 (da)
WO (1)	WO2003062200A2 (da)
ZA (1)	ZA200404999B (da)

Families Citing this family (44)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US7273883B2 (en) *	2000-09-14	2007-09-25	Allergan, Inc.	Prostaglandin EP4 antagonist
US7217725B2 (en) *	2000-09-14	2007-05-15	Allergan, Inc.	Prostaglandin D2 antagonist
AR038136A1 (es) *	2002-01-24	2004-12-29	Merck Frosst Canada Inc	Cicloalcanindoles con sustitucion con fluor composiciones que contienen estos compuestos y metodos de tratamiento
AR041089A1 (es)	2003-05-15	2005-05-04	Merck & Co Inc	Procedimiento y composiciones farmaceutiicas para tratar aterosclerosis, dislipidemias y afecciones relacionadas
WO2004104205A2 (en) *	2003-05-16	2004-12-02	Merck & Co., Inc.	Enzymatic preparation of chiral indole esters
CA2526013A1 (en) *	2003-05-20	2004-12-02	Merck Frosst Canada Ltd.	Fluoro-methanesulfonyl-substituted cycloalkanoindoles and their use as prostaglandin d2 antagonists
US20080153817A1 (en) *	2003-08-07	2008-06-26	Dirk Beher	Treatment for Alzheimer's Disease and Related Conditions
PE20050483A1 (es)	2003-10-31	2005-08-25	Arena Pharm Inc	Derivados de tetrazol de formula (i), sus composiciones farmaceuticas y procesos para producir composiciones farmaceuticas
US7019022B2 (en) *	2003-12-15	2006-03-28	Merck Frosst Canada & Co.	Substituted tetrahydrocarbazole and cyclopentanoindole derivatives
WO2005095397A1 (en)	2004-03-11	2005-10-13	Actelion Pharmaceuticals Ltd	Tetrahydropyridoindole derivatives
PL1737820T3 (pl) *	2004-04-02	2008-05-30	Merck Sharp & Dohme	Sposób asymetrycznego uwodorniania nadający się do wytwarzania pochodnych cykloalkanoindoli
HN2005000795A (es) *	2004-10-15	2010-08-19	Aventis Pharma Inc	Pirimidinas como antagonistas del receptor de prostaglandina d2
WO2006052798A2 (en) *	2004-11-08	2006-05-18	Merck & Co., Inc.	Method of treating pathological blushing
PE20060949A1 (es)	2004-12-23	2006-10-11	Arena Pharm Inc	Derivados fusionados de pirazol como agonistas del receptor de niacina
WO2006068162A1 (ja) *	2004-12-24	2006-06-29	Shionogi & Co., Ltd.	慢性閉塞性肺疾患の治療剤
CA2594280C (en) *	2004-12-27	2013-04-23	Anja Fecher	2,3,4,9-tetrahydro-1h-carbazole derivatives as crth2 receptor antagonists
AU2006214018A1 (en) *	2005-02-17	2006-08-24	Merck Sharp & Dohme Corp.	Method of treating atherosclerosis, dyslipidemias and related conditions
JP2008536846A (ja) *	2005-04-13	2008-09-11	メルクエンドカムパニーインコーポレーテッド	ナイアシン受容体アゴニスト、かかる化合物を含有する組成物及び治療方法
WO2007010964A1 (ja)	2005-07-22	2007-01-25	Shionogi & Co., Ltd.	Ｐｇｄ２受容体アンタゴニスト活性を有するインドール誘導体
US7842692B2 (en)	2005-07-22	2010-11-30	Shionogi & Co., Ltd.	Azaindole derivative having PGD2 receptor antagonistic activity
WO2007029629A1 (ja)	2005-09-06	2007-03-15	Shionogi & Co., Ltd.	Ｐｇｄ２受容体アンタゴニスト活性を有するインドールカルボン酸誘導体
US9254293B2 (en)	2006-06-16	2016-02-09	The Trustees Of The University Of Pennsylvania	Methods and compositions for inhibiting or reducing hair loss, acne, rosacea, prostate cancer, and BPH
SI2051962T1 (sl)	2006-08-07	2012-02-29	Actelion Pharmaceuticals Ltd	Derivati (3-amino-1,2,3,4-tetrahidro-9h-karbazol-9-il)-ocetne kisline
US20100260841A1 (en) *	2007-02-08	2010-10-14	Paolini John F	Method of Treating Atherosclerosis, Dyslipidemias and Related Conditions
US20090076117A1 (en) *	2007-09-17	2009-03-19	Protia, Llc	Deuterium-enriched laropiprant
JP2011526281A (ja)	2008-06-24	2011-10-06	アミラファーマシューティカルズ，インク．	プロスタグランジンｄ２受容体のシクロアルカン［ｂ］インドールアンタゴニスト
WO2010030360A1 (en)	2008-09-11	2010-03-18	Arena Pharmaceuticals, Inc.	3H-IMIDAZO[4,5-b]PYRIDIN-5-OL DERIVATIVES USEFUL IN THE TREATMENT OF GPR81 RECEPTOR DISORDERS
CA2737618A1 (en)	2008-09-25	2010-04-01	Merck Frosst Canada Ltd.	Beta-carboline sulphonylurea derivatives as ep4 receptor antagonists
GB2463788B (en) *	2008-09-29	2010-12-15	Amira Pharmaceuticals Inc	Heteroaryl antagonists of prostaglandin D2 receptors
GB2465062B (en)	2008-11-06	2011-04-13	Amira Pharmaceuticals Inc	Cycloalkane(B)azaindole antagonists of prostaglandin D2 receptors
US9180114B2 (en) *	2008-11-26	2015-11-10	President And Fellows Of Harvard College	Neurodegenerative diseases and methods of modeling
US8882678B2 (en) *	2009-03-13	2014-11-11	Atrium Medical Corporation	Pleural drainage system and method of use
WO2011117798A1 (en)	2010-03-22	2011-09-29	Actelion Pharmaceuticals Ltd	3-(heteroaryl-amino)-1,2,3,4-tetrahydro-9h-carbazole derivatives and their use as prostaglandin d2 receptor modulators
CA2830204C (en)	2011-04-14	2019-04-09	Actelion Pharmaceuticals Ltd	7-(heteroaryl-amino)-6,7,8,9-tetrahydropyrido[1,2-a]indol acetic acid derivatives and their use as prostaglandin d2 receptor modulators
JP5841361B2 (ja) *	2011-06-29	2016-01-13	壽製薬株式会社	三環性化合物及びそれを含有する医薬組成物
AR088377A1 (es) *	2011-10-20	2014-05-28	Siena Biotech Spa	Proceso para la preparacion de 6-cloro-2,3,4,9-tetrahidro-1h-carbazol-1-carboxamida y compuestos intermedios de esta
CN102659664B (zh) *	2012-03-28	2015-01-21	中国计量学院	合成分离拉洛皮兰及其类似物的方法
FR3000399B1 (fr) *	2012-12-31	2015-03-27	Galderma Res & Dev	Utilisation topique du laropiprant pour le traitement de la rosacee
FR3000395A1 (fr) *	2012-12-31	2014-07-04	Galderma Res & Dev	Combinaison de laropiprant et d'oxymetazoline pour le traitement de la rosacee
TWI649321B (zh)	2014-03-17	2019-02-01	瑞士商愛杜西亞製藥有限公司	氮雜吲哚乙酸衍生物及彼等作為前列腺素ｄ２受體調節劑之用途
CN106103437A (zh)	2014-03-18	2016-11-09	埃科特莱茵药品有限公司	氮杂吲哚乙酸衍生物及其作为前列腺素d2受体调节剂的用途
US20180021302A1 (en)	2015-02-13	2018-01-25	Institut National De La Sante Et De La Recherche Medicale (Inserm)	Ptgdr-1 and/or ptgdr-2 antagonists for preventing and/or treating systemic lupus erythematosus
AU2016323262B2 (en)	2015-09-15	2020-11-19	Idorsia Pharmaceuticals Ltd	Crystalline forms
CN111886315B (zh)	2018-03-19	2023-06-30	三井化学株式会社	显示元件用密封材及其固化物、有机el元件用框密封材以及有机el元件用面密封材

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US3535326A (en) *	1967-03-06	1970-10-20	Sumitomo Chemical Co	Certain tetrahydro carboline derivatives
BE787444A (fr) *	1971-08-13	1973-02-12	Hoffmann La Roche	Composes polycycliques
US4009181A (en) *	1973-01-22	1977-02-22	Hoffmann-La Roche Inc.	Cyclopenta[b]indole-2-carboxylic acids and derivatives thereof
US4057559A (en) *	1973-10-01	1977-11-08	American Home Products Corporation	Carbazole acetic acid derivatives
US4166452A (en)	1976-05-03	1979-09-04	Generales Constantine D J Jr	Apparatus for testing human responses to stimuli
US4256108A (en)	1977-04-07	1981-03-17	Alza Corporation	Microporous-semipermeable laminated osmotic system
US4265874A (en)	1980-04-25	1981-05-05	Alza Corporation	Method of delivering drug with aid of effervescent activity generated in environment of use
ES2038653T3 (es) *	1986-01-23	1993-08-01	Merck Frosst Canada Inc.	Acidos 1-alcanoicos tetrahidrocarbazol.
US4808608A (en) *	1986-01-23	1989-02-28	Merck & Co., Inc.	Tetrahydrocarbazole 1-alkanoic acids, pharmaceutical compositions and use
US5021447A (en) *	1986-01-23	1991-06-04	Merck Frosst Canada, Inc.	Tetrahydrocarbazole 1-alkanoic acids and pharmaecutical compositions
US4940719A (en) *	1986-03-27	1990-07-10	Merck Frosst Canada, Inc.	Tetrahydrocarbazole esters, pharmaceutical compositions and use
US4775680A (en) *	1987-07-21	1988-10-04	Merck & Co., Inc.	Cyclohept[b]indolealkanoic acids, pharmaceutical compositions and use
US5221678A (en)	1990-07-26	1993-06-22	Merck Frosst Canada, Inc.	(quinolin-2-ylmethoxy)tetrahydrocarbazoles as inhibitors of the biosynthesis of leukotrienes
GB9101375D0 (en)	1991-01-22	1991-03-06	Erba Carlo Spa	N-imidazolyl derivatives of substituted tetrahydrocarbazole and cyclohepht(b)indole
AU693143B2 (en)	1993-12-06	1998-06-25	Cytel Corporation	CS-1 peptidomimetics, compositions and methods of using the same
US5510332A (en)	1994-07-07	1996-04-23	Texas Biotechnology Corporation	Process to inhibit binding of the integrin α4 62 1 to VCAM-1 or fibronectin and linear peptides therefor
CA2193508A1 (en)	1994-07-11	1996-01-25	Eugene D. Thorsett	Inhibitors of leukocyte adhesion
US5811391A (en)	1994-08-25	1998-09-22	Cytel Corporation	Cyclic CS-1 peptidomimetics, compositions and methods of using same
GB9524630D0 (en)	1994-12-24	1996-01-31	Zeneca Ltd	Chemical compounds
US6306840B1 (en)	1995-01-23	2001-10-23	Biogen, Inc.	Cell adhesion inhibitors
WO1996031206A2 (en)	1995-04-07	1996-10-10	Warner-Lambert Company	Flavones and coumarins as agents for the treatment of atherosclerosis
WO1996040781A1 (en)	1995-06-07	1996-12-19	Tanabe Seiyaku Co., Ltd.	CYCLIC PEPTIDE INHIBITORS OF β1 AND β2 INTEGRIN-MEDIATED ADHESION
DK0837052T3 (da)	1995-06-21	2007-01-02	Shionogi & Co	Bicykliske aminoderivater og PGD2-antagonist indeholdende disse
AU6311996A (en)	1995-07-06	1997-02-05	Zeneca Limited	Peptide inhibitors of fibronectine
US6248713B1 (en)	1995-07-11	2001-06-19	Biogen, Inc.	Cell adhesion inhibitors
BR9714016A (pt)	1996-12-13	2000-02-29	Shionogi & Co	Derivados de benzotiofenocarboxamida e antagonistas a pgd2, que compreendem os mesmos
KR100422920B1 (ko)	1998-06-03	2004-03-12	시오노기세이야쿠가부시키가이샤	Ｐｇｄ2 길항제를 포함하는 소양증을 위한 치료제
US20010047027A1 (en)	2000-04-12	2001-11-29	Marc Labelle	Prostaglandin D2 receptor antagonists
US6410583B1 (en) *	2000-07-25	2002-06-25	Merck Frosst Canada & Co.	Cyclopentanoindoles, compositions containing such compounds and methods of treatment
AR038136A1 (es) *	2002-01-24	2004-12-29	Merck Frosst Canada Inc	Cicloalcanindoles con sustitucion con fluor composiciones que contienen estos compuestos y metodos de tratamiento
US7019022B2 (en) *	2003-12-15	2006-03-28	Merck Frosst Canada & Co.	Substituted tetrahydrocarbazole and cyclopentanoindole derivatives

2003
- 2003-01-14 AR ARP030100093A patent/AR038136A1/es active IP Right Grant
- 2003-01-16 JO JO20032A patent/JO2481B1/en active
- 2003-01-16 MY MYPI20030139A patent/MY137040A/en unknown
- 2003-01-21 PE PE2003000068A patent/PE20030982A1/es not_active Application Discontinuation
- 2003-01-21 US US10/348,403 patent/US20030158246A1/en not_active Abandoned
- 2003-01-22 AU AU2003202343A patent/AU2003202343B2/en not_active Ceased
- 2003-01-22 DE DE60324767T patent/DE60324767D1/de not_active Expired - Lifetime
- 2003-01-22 EA EA200400971A patent/EA006134B1/ru not_active IP Right Cessation
- 2003-01-22 NZ NZ533786A patent/NZ533786A/en not_active IP Right Cessation
- 2003-01-22 JP JP2003562082A patent/JP4008885B2/ja not_active Expired - Fee Related
- 2003-01-22 GE GE5688A patent/GEP20074078B/en unknown
- 2003-01-22 RS RSP-2010/0338A patent/RS20100338A/en unknown
- 2003-01-22 SI SI200331470T patent/SI1470107T1/sl unknown
- 2003-01-22 IL IL16282503A patent/IL162825A0/xx unknown
- 2003-01-22 CN CN201010164113A patent/CN101851191A/zh active Pending
- 2003-01-22 PT PT08105552T patent/PT2045241E/pt unknown
- 2003-01-22 DK DK08105552.7T patent/DK2045241T3/da active
- 2003-01-22 KR KR1020047011489A patent/KR100859230B1/ko not_active IP Right Cessation
- 2003-01-22 EP EP03700740A patent/EP1470107B1/en not_active Expired - Lifetime
- 2003-01-22 PL PL370427A patent/PL208527B1/pl not_active IP Right Cessation
- 2003-01-22 KR KR1020077010548A patent/KR20070056166A/ko not_active Application Discontinuation
- 2003-01-22 EP EP08105552A patent/EP2045241B1/en not_active Expired - Lifetime
- 2003-01-22 DK DK03700740T patent/DK1470107T3/da active
- 2003-01-22 BR BR0307050-6A patent/BR0307050A/pt not_active IP Right Cessation
- 2003-01-22 RS YU62404A patent/RS51672B/en unknown
- 2003-01-22 UA UA20040807066A patent/UA75520C2/uk unknown
- 2003-01-22 ES ES03700740T patent/ES2316717T3/es not_active Expired - Lifetime
- 2003-01-22 WO PCT/CA2003/000084 patent/WO2003062200A2/en active Application Filing
- 2003-01-22 CA CA002471952A patent/CA2471952C/en not_active Expired - Fee Related
- 2003-01-22 ES ES08105552T patent/ES2391747T3/es not_active Expired - Lifetime
- 2003-01-22 PT PT03700740T patent/PT1470107E/pt unknown
- 2003-01-22 DE DE122009000022C patent/DE122009000022I1/de active Pending
- 2003-01-22 CN CNA038026759A patent/CN1902176A/zh active Pending
- 2003-01-22 SI SI200332197T patent/SI2045241T1/sl unknown
- 2003-01-22 CN CNA2007101263979A patent/CN101092388A/zh active Pending
- 2003-01-22 MX MXPA04007167A patent/MXPA04007167A/es active IP Right Grant
- 2003-01-22 AT AT03700740T patent/ATE414690T1/de active
- 2003-01-22 EP EP10182463.9A patent/EP2295409B1/en not_active Expired - Lifetime
- 2003-01-22 US US10/502,380 patent/US7317036B2/en not_active Expired - Lifetime
- 2003-01-23 TW TW092101476A patent/TWI259080B/zh not_active IP Right Cessation
- 2003-01-24 DO DO2003000566A patent/DOP2003000566A/es unknown
- 2003-01-25 EG EG2003010067A patent/EG24978A/xx active
2004
- 2004-06-21 IS IS7329A patent/IS2633B/is unknown
- 2004-06-24 ZA ZA200404999A patent/ZA200404999B/en unknown
- 2004-07-01 IL IL162825A patent/IL162825A/en active IP Right Grant
- 2004-07-19 HR HR20040665 patent/HRP20040665B1/xx not_active IP Right Cessation
- 2004-07-22 EC EC2004005203A patent/ECSP045203A/es unknown
- 2004-08-24 NO NO20043536A patent/NO327322B1/no not_active IP Right Cessation
2005
- 2005-11-04 US US11/266,919 patent/US20060069148A1/en not_active Abandoned
2007
- 2007-02-26 JP JP2007045469A patent/JP2007186521A/ja active Pending
- 2007-03-02 NO NO20071193A patent/NO20071193L/no not_active Application Discontinuation
- 2007-07-23 US US11/880,557 patent/US7618994B2/en not_active Expired - Lifetime
2008
- 2008-01-17 IL IL188844A patent/IL188844A0/en unknown
2009
- 2009-02-09 CY CY20091100147T patent/CY1108841T1/el unknown
- 2009-02-20 NL NL300377C patent/NL300377I2/nl unknown
- 2009-02-27 LU LU91534C patent/LU91534I2/fr unknown
- 2009-03-12 FR FR09C0010C patent/FR09C0010I2/fr active Active
- 2009-03-31 CY CY200900004C patent/CY2009004I2/el unknown
- 2009-06-19 NO NO2009013C patent/NO2009013I2/no unknown
- 2009-09-30 US US12/570,859 patent/US20100081696A1/en not_active Abandoned
2010
- 2010-03-01 IS IS8887A patent/IS8887A/is unknown
2012
- 2012-01-19 US US13/353,974 patent/US20120115921A1/en not_active Abandoned
- 2012-09-17 CY CY20121100844T patent/CY1113330T1/el unknown

Also Published As

Publication number	Publication date
NO327322B1 (no)	2009-06-08
US20050124680A1 (en)	2005-06-09
AU2003202343B2 (en)	2007-07-12
ES2391747T3 (es)	2012-11-29
CY2009004I1 (el)	2009-11-04
CA2471952C (en)	2008-04-01
MXPA04007167A (es)	2004-10-29
KR100859230B1 (ko)	2008-09-18
LU91534I2 (fr)	2009-04-27
EA006134B1 (ru)	2005-10-27
BR0307050A (pt)	2004-10-26
ES2316717T3 (es)	2009-04-16
CN101092388A (zh)	2007-12-26
EG24978A (en)	2011-04-03
PL208527B1 (pl)	2011-05-31
TWI259080B (en)	2006-08-01
US20080033028A1 (en)	2008-02-07
SI1470107T1 (sl)	2009-04-30
GEP20074078B (en)	2007-03-26
JP4008885B2 (ja)	2007-11-14
IL162825A (en)	2010-12-30
PT1470107E (pt)	2009-01-30
RS62404A (en)	2006-12-15
CY1113330T1 (el)	2016-06-22
NO2009013I2 (no)	2012-08-27
CN1902176A (zh)	2007-01-24
ATE414690T1 (de)	2008-12-15
HRP20040665A2 (en)	2005-04-30
CY1108841T1 (el)	2011-04-06
JO2481B1 (en)	2009-01-20
US20100081696A1 (en)	2010-04-01
US20030158246A1 (en)	2003-08-21
PL370427A1 (en)	2005-05-30
TW200302090A (en)	2003-08-01
IL188844A0 (en)	2009-02-11
RS51672B (en)	2011-10-31
EP2295409A1 (en)	2011-03-16
WO2003062200A2 (en)	2003-07-31
CY2009004I2 (el)	2009-11-04
US7317036B2 (en)	2008-01-08
US7618994B2 (en)	2009-11-17
WO2003062200A3 (en)	2003-12-04
EP2295409B1 (en)	2014-07-02
JP2005518413A (ja)	2005-06-23
SI2045241T1 (sl)	2012-11-30
KR20040075109A (ko)	2004-08-26
IS7329A (is)	2004-06-21
DE122009000022I1 (de)	2009-08-06
DOP2003000566A (es)	2003-09-15
ECSP045203A (es)	2004-09-28
DK1470107T3 (da)	2009-03-09
US20120115921A1 (en)	2012-05-10
FR09C0010I2 (da)	2009-12-18
CN101851191A (zh)	2010-10-06
FR09C0010I1 (da)	2009-04-17
IS8887A (is)	2010-03-01
US20060069148A1 (en)	2006-03-30
MY137040A (en)	2008-12-31
CA2471952A1 (en)	2003-07-31
UA75520C2 (en)	2006-04-17
EP1470107B1 (en)	2008-11-19
RS20100338A (en)	2011-06-30
HRP20040665B1 (en)	2012-11-30
IS2633B (is)	2010-06-15
PT2045241E (pt)	2012-09-26
IL162825A0 (en)	2005-11-20
NO20043536L (no)	2004-08-24
DE60324767D1 (de)	2009-01-02
AR038136A1 (es)	2004-12-29
EP1470107A2 (en)	2004-10-27
PE20030982A1 (es)	2003-11-19
AU2003202343C1 (en)	2003-09-02
KR20070056166A (ko)	2007-05-31
ZA200404999B (en)	2006-05-31
JP2007186521A (ja)	2007-07-26
NO20071193L (no)	2004-08-24
NL300377I2 (nl)	2009-08-03
NZ533786A (en)	2006-11-30
NO2009013I1 (no)	2009-06-29
EP2045241B1 (en)	2012-07-04
EP2045241A1 (en)	2009-04-08
NL300377I1 (nl)	2009-05-06
EA200400971A1 (ru)	2004-12-30

Publication	Publication Date	Title
DK2045241T3 (da)	2012-10-15	Fluorsubstituerede cycloalkanoindoler og anvendelse deraf som prostaglandin D2-receptorantagonister
FR18C1024I2 (fr)	2019-05-17	Derives d'heterocyclocarboxamide
IS7801A (is)	2005-04-14	Púrín efnasambönd og notkun þeirra sem kannabinóíð viðtaka bindla
DK1501815T3 (da)	2007-04-02	Substituerede phenylacetamider og anvendelse deraf som glucokinaseaktivatorer
NO20043803L (no)	2005-05-24	Substituerte amider som er aktive i cannabinoid 1-reseptoren
NO20041922L (no)	2004-06-01	Benzamid og heteroarylamid som P2X7-reseptorantagonister
ATE416168T1 (de)	2008-12-15	Modulatoren des vanilloidrezeptors
DK1345920T3 (da)	2006-08-14	Hidtil ukendte sulfamider og anvendelse deraf som endothelinreceptorantagonister
IS7041A (is)	2003-11-17	5-HT viðtakabindlar og notkun þeirra
DE60308953D1 (de)	2006-11-23	Nähfadenanker
DE60320067D1 (de)	2008-05-15	Nähfadenankersystem
NO20030471D0 (no)	2003-01-30	Karboksamidforbindelser og deres anvendelse som antagonister for en 11CBY-reseptor
NO20041008L (no)	2004-03-10	Karbazolderivater og anvendelse derav som NPY5 reseptor antagonister
ATE394375T1 (de)	2008-05-15	Zusammensetzung enthaltend einen tachykininrezeptor antagonisten und einen serotonin-wiederaufnahmehemmer
DK1581518T3 (da)	2011-06-06	Substituerede 1-piperidin-4-yl-4-pyrrolidin-3-yl-piperazin-derivater og deres anvendelse som neurokinin antagonister
FI20060188A (fi)	2006-02-24	Modifioidut IL-4-muteiinin reseptorin antagonistit
NO20044373L (no)	2004-10-14	Azetidinderivater som CCR-3-reseptorantagonister
NO20025762D0 (no)	2002-11-29	Bicykliske cykloheksylaminer og anvendelse derav som NMDA- reseptorantagonister
DK1487778T3 (da)	2012-08-06	Substituerede 4 aminocyclohexanoler
NO20053598D0 (no)	2005-07-22	Substituerte 1-piperidin-3-yl-4-pyrrolidin-4-yl-piperazinderivater og deres anvendelse som nevrokininantagonister.
FR2847624B1 (fr)	2008-11-14	Joint spherique
NO20055725D0 (no)	2005-12-02	Glutamatreseptorantagonister som neurobeskyttende midler
FI20020049A0 (fi)	2002-01-11	Sõhk÷keskusrakenne
SE0202986D0 (sv)	2002-10-09	Naphthamide derivatives and their use
ITPG20020004U1 (it)	2003-11-17	Sgabello di emergenza